Literature DB >> 14758299

Effect of methylphenidate on vital signs and adverse effects in adults with traumatic brain injury.

Joseph P Alban1, Monica M Hopson, Vivian Ly, John Whyte.   

Abstract

OBJECTIVE: To study methylphenidate's adverse effects and impact on vital signs within the adult traumatic brain injury population.
DESIGN: Thirty-five adults with traumatic brain injury enrolled in a double-blind, placebo-controlled, 6-wk crossover study of methylphenidate, given in a dose of 0.3 mg/kg/dose, twice a day. Vital signs were taken by trained clinicians and research assistants. Participants filled out weekly questionnaires pertaining to the adverse effects.
RESULTS: Poor appetite was the only adverse effect related to methylphenidate. Other adverse effects commonly associated with methylphenidate, such as insomnia, rapid heart rate, and anxiety, were not found to be significantly related to the medication. The average rise in mean arterial pressure on methylphenidate was 2.5 mm. Methylphenidate showed a stronger impact on pulse, with an average increase of 7 beats/min. Baseline vital signs did not predict the degree of increase on methylphenidate.
CONCLUSION: Methylphenidate appears to be safe for the adult population with traumatic brain injury. However, because a few individuals experienced significant changes in vital signs and adverse effects, all patients should be monitored.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14758299     DOI: 10.1097/01.phm.0000112308.68586.1d

Source DB:  PubMed          Journal:  Am J Phys Med Rehabil        ISSN: 0894-9115            Impact factor:   2.159


  6 in total

1.  Information for physicians and pharmacists about drugs that might cause dry mouth: a study of monographs and published literature.

Authors:  Caroline T Nguyen; Michael I MacEntee; Barbara Mintzes; Thomas L Perry
Journal:  Drugs Aging       Date:  2014-01       Impact factor: 3.923

Review 2.  Pharmacology of traumatic brain injury: where is the "golden bullet"?

Authors:  Kathryn Beauchamp; Haitham Mutlak; Wade R Smith; Esther Shohami; Philip F Stahel
Journal:  Mol Med       Date:  2008-08-18       Impact factor: 6.354

Review 3.  Pharmacotherapy of traumatic brain injury: state of the science and the road forward: report of the Department of Defense Neurotrauma Pharmacology Workgroup.

Authors:  Ramon Diaz-Arrastia; Patrick M Kochanek; Peter Bergold; Kimbra Kenney; Christine E Marx; Col Jamie B Grimes; L T C Yince Loh; L T C Gina E Adam; Devon Oskvig; Kenneth C Curley; Wanda Salzer
Journal:  J Neurotrauma       Date:  2014-01-15       Impact factor: 5.269

4.  Treatment of post-traumatic cognitive impairments.

Authors:  Hal S Wortzel; David B Arciniegas
Journal:  Curr Treat Options Neurol       Date:  2012-10       Impact factor: 3.598

Review 5.  Stimulant Therapy Utilization for Neurocognitive Deficits in Mild Traumatic Brain Injury.

Authors:  Eric E Coris; Byron Moran; Kevin Sneed; Gianluca Del Rossi; Bradford Bindas; Shaan Mehta; Dusty Narducci
Journal:  Sports Health       Date:  2021-07-22       Impact factor: 4.355

Review 6.  Challenges of Delirium Management in Patients with Traumatic Brain Injury: From Pathophysiology to Clinical Practice.

Authors:  Shawniqua Williams Roberson; Mayur B Patel; Wojciech Dabrowski; E Wesley Ely; Cezary Pakulski; Katarzyna Kotfis
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.